Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ZURA Stock Forecast 2026-2027
$5.37
Current Price
$509.51M
Market Cap
Buy 7
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ZURA Price Targets
+384.2%
To High Target of $26.00
+179.3%
To Median Target of $15.00
+104.8%
To Low Target of $11.00
ZURA Price Momentum
-6.1%
1 Week Change
-2.4%
1 Month Change
+292.0%
1 Year Change
+2.5%
Year-to-Date Change
-27.8%
From 52W High of $7.44
+448.0%
From 52W Low of $0.98
📊 TOP ANALYST CALLS
Did ZURA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Zura Bio is one of their latest high-conviction picks.
Latest ZURA Stock Price Targets & Analyst Predictions
Based on our analysis of 15 Wall Street analysts, ZURA has a bullish consensus with a median price target of $15.00 (ranging from $11.00 to $26.00). The overall analyst rating is Strong Buy (9.7/10). Currently trading at $5.37, the median forecast implies a 179.3% upside. This outlook is supported by 7 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yasmeen Rahimi at Piper Sandler, projecting a 384.2% upside. Conversely, the most conservative target is provided by Daniil Gataulin at Chardan Capital, suggesting a 104.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ZURA Analyst Ratings
7
Buy
0
Hold
0
Sell
ZURA Price Target Range
Low
$11.00
Average
$15.00
High
$26.00
Current: $5.37
Latest ZURA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ZURA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 23, 2026 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $11.00 |
| Mar 20, 2026 | Oppenheimer | Justin Kim | Outperform | Maintains | $15.00 |
| Feb 9, 2026 | Wedbush | Martin Fan | Outperform | Initiates | $15.00 |
| Nov 14, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $10.00 |
| Nov 13, 2025 | Clear Street | Kaveri Pohlman | Buy | Initiates | $18.00 |
| Sep 30, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $10.00 |
| Aug 19, 2025 | HC Wainwright & Co. | Mitchell S. Kapoor | Neutral | Maintains | $2.00 |
| Aug 15, 2025 | Oppenheimer | Justin Kim | Outperform | Maintains | $16.00 |
| Aug 15, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $10.00 |
| May 9, 2025 | Oppenheimer | Jeff Jones | Outperform | Maintains | $17.00 |
| Apr 3, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Maintains | $3.00 |
| Mar 26, 2025 | Chardan Capital | Matthew Barcus | Buy | Maintains | $10.00 |
| Mar 26, 2025 | Guggenheim | Yatin Suneja | Buy | Reiterates | $15.00 |
| Mar 26, 2025 | Oppenheimer | Jeff Jones | Outperform | Maintains | $19.00 |
| Dec 24, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Reiterates | $5.00 |
| Dec 11, 2024 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Nov 18, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Reiterates | $5.00 |
| Nov 11, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Reiterates | $5.00 |
| Nov 9, 2024 | Chardan Capital | Buy | Maintains | $N/A | |
| Nov 8, 2024 | Chardan Capital | Matthew Barcus | Buy | Maintains | $12.00 |
Zura Bio Ltd. (ZURA) Competitors
The following stocks are similar to Zura Bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Zura Bio Ltd. (ZURA) Financial Data
Zura Bio Ltd. has a market capitalization of $509.51M with a P/E ratio of 7.9x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -52.5%.
Valuation Metrics
Market Cap
$509.51M
Enterprise Value
$441.85M
P/E Ratio
7.9x
PEG Ratio
-58.1x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+21.5%
Current Ratio
9.1x
Debt/Equity
0.0x
ROE
-52.5%
ROA
-32.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Zura Bio Ltd. (ZURA) Business Model
About Zura Bio Ltd.
What They Do
Develops novel dual-pathway antibodies for immunology.
Business Model
Zura Bio Ltd. operates as a clinical-stage biopharmaceutical company focused on developing dual-pathway antibodies to treat autoimmune and inflammatory diseases. The company generates revenue through collaborations, licensing agreements, and potential commercialization of its innovative therapeutic agents as they progress through clinical trials and receive regulatory approval.
Additional Information
The company’s lead product, tibulizumab, is currently in Phase 2 trials targeting conditions such as hidradenitis suppurativa and systemic sclerosis. Zura Bio's strategic focus on dual antagonism aims to enhance treatment efficacy for patients with diverse autoimmune disorders. The management team comprises experienced biotechnology and pharmaceutical professionals, positioning the company well in the immunology sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
40
CEO
Dr. Sandeep C. Kulkarni M.D.
Country
United States
IPO Year
2023
Website
zurabio.comZura Bio Ltd. (ZURA) Latest News & Analysis
Latest News
Quick Summary
Zura Bio Limited (Nasdaq: ZURA) reported strong execution in 2025, with progress in its Phase 2 programs for autoimmune and inflammatory diseases. Financial results were also disclosed.
Why It Matters
Zura Bio's strong execution and progress in Phase 2 programs signal potential growth, impacting future stock performance and investor confidence in the biotech sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Zura Bio Limited (Nasdaq: ZURA) announced that its Phase 2 TibuSURE trial design for tibulizumab in systemic sclerosis has been accepted for presentation at the Systemic Sclerosis World Congress.
Why It Matters
Zura Bio's Phase 2 trial acceptance for presentation highlights potential advancements in treating systemic sclerosis, which could attract investor interest and impact stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Zura Bio Limited (Nasdaq: ZURA) will participate in the Leerink Global Healthcare Conference in Miami on March 10, focusing on its advancements in autoimmune and inflammatory disease treatments.
Why It Matters
Zura Bio's participation in investor conferences signals its commitment to transparency and engagement, potentially attracting interest and investment in its innovative treatments for autoimmune diseases.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Zura Bio Limited (Nasdaq: ZURA) has priced an underwritten public offering of 18.2 million Class A ordinary shares at $6.25 per share to support its biotech developments.
Why It Matters
Zura Bio's public offering at $6.25 per share indicates funding for growth, impacting share liquidity and investor sentiment on its pipeline for autoimmune treatments.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Zura Bio Limited (Nasdaq: ZURA) closed a public offering of 21.2 million Class A ordinary shares on February 26, 2026, aimed at funding its development of treatments for autoimmune diseases.
Why It Matters
Zura Bio's public offering indicates capital raising efforts, impacting liquidity and future growth potential, which can affect stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D.
1 month ago
Quick Summary
Zura Bio Limited (Nasdaq: ZURA) announced the appointments of Mark Eisner and Ajay Nirula to its Board of Directors, effective February 21, 2026, as part of a leadership transition.
Why It Matters
Board appointments can signal strategic shifts and enhance governance. New members with medical expertise may boost investor confidence in Zura's potential for innovation and growth in biotech.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About ZURA Stock
What is Zura Bio Ltd.'s (ZURA) stock forecast for 2026?
Based on our analysis of 15 Wall Street analysts, Zura Bio Ltd. (ZURA) has a median price target of $15.00. The highest price target is $26.00 and the lowest is $11.00.
Is ZURA stock a good investment in 2026?
According to current analyst ratings, ZURA has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.37. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ZURA stock?
Wall Street analysts predict ZURA stock could reach $15.00 in the next 12 months. This represents a 179.3% increase from the current price of $5.37. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Zura Bio Ltd.'s business model?
Zura Bio Ltd. operates as a clinical-stage biopharmaceutical company focused on developing dual-pathway antibodies to treat autoimmune and inflammatory diseases. The company generates revenue through collaborations, licensing agreements, and potential commercialization of its innovative therapeutic agents as they progress through clinical trials and receive regulatory approval.
What is the highest forecasted price for ZURA Zura Bio Ltd.?
The highest price target for ZURA is $26.00 from Yasmeen Rahimi at Piper Sandler, which represents a 384.2% increase from the current price of $5.37.
What is the lowest forecasted price for ZURA Zura Bio Ltd.?
The lowest price target for ZURA is $11.00 from Daniil Gataulin at Chardan Capital, which represents a 104.8% increase from the current price of $5.37.
What is the overall ZURA consensus from analysts for Zura Bio Ltd.?
The overall analyst consensus for ZURA is bullish. Out of 15 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $15.00.
How accurate are ZURA stock price projections?
Stock price projections, including those for Zura Bio Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 21, 2026 1:29 PM UTC